Can trametinib be reimbursed by medical insurance in 2023?

According to the domestic medical insurance coverage standards, in 2023, patients can use medical insurance to purchase Trametinib (Trametinib) for reimbursement, but it may only be suitable for treatment with dabrafenib mesylateBRAF Patients with V600 mutation-positive unresectable or metastatic melanoma and adjuvant therapy after complete resection, combined with dabrafenib mesylate, are suitable for the treatment of patients with BRAF V600 mutation-positive metastatic non-small cell lung cancer. The reimbursement ratios and prices are also different in different regions.

Trametinib is an anti-cancer drug approved by the U.S. Food and Drug Administration (FDA) and is commonly used to treat malignant tumors such as advanced non-small cell lung cancer, melanoma, and unresectable or metastatic solid tumors with BRAF V600E or V600K mutations. The mechanism of action of trametinib is to inhibit the activity of MEK protein, thereby blocking the signaling pathways for tumor cell proliferation and survival. In this way, trametinib slows or stops the growth and spread of tumors. In clinical trials, trametinib has shown significant therapeutic effects in certain tumor types.

The price of domestic trametinib original drug is around 10,000-20,000 yuan, which is expensive. The price of the Turkish version of the original drug Trametinib listed overseas is around RMB 7,900 (the price may fluctuate due to the exchange rate). The price of the generic version of Trametinib produced by the Lao pharmaceutical factory is around RMB 2,950 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of foreign generic drugs are basically the same as those of the domestic and foreign original drugs.